ENvue Medical’s UroShield® Kit Secures Reimbursement in the UK

Core Insights - ENvue Medical's UroShield® Kit has been added to the UK NHS Drug Tariff Part IX, enabling nationwide prescription reimbursement across the UK, which is expected to significantly enhance market access and demand for the product [1][3] - The company has received an initial purchase order from Peak Medical, indicating early commercial demand following the inclusion in the NHS Drug Tariff [2][3] - The UroShield® Kit is designed to reduce catheter-associated urinary tract infections (CAUTIs) and catheter blockages, addressing a significant healthcare challenge in the UK where catheter prevalence is approximately 6-7% in long-term care populations [3][6] Company Developments - The inclusion of UroShield® in the NHS Drug Tariff is seen as a major commercial and reimbursement milestone, removing barriers to access and enabling scalable NHS prescribing [3] - The initial purchase order from Peak Medical provides early revenue visibility for ENvue Medical heading into 2026, marking a first step in establishing a presence in European markets [3] - ENvue Medical is committed to assessing reimbursement frameworks and market access pathways in select European countries as part of its long-term portfolio strategy [3] Market Context - Long-term urinary catheterization is common in the UK, with a significant risk of CAUTIs, which are among the most prevalent device-associated healthcare-acquired infections globally [3][6] - The UroShield® Kit utilizes low-frequency ultrasonic energy to inhibit biofilm formation, thereby reducing the risk of CAUTIs and improving patient outcomes [3][5] - The partnership with Peak Medical is expected to enhance the distribution of innovative, non-invasive solutions within the UK healthcare system [2][3]